Loading chart...




The current price of ME is 0 USD — it has increased 0
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Wall Street analysts forecast ME stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ME is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
23andMe Holding Co. revenue for the last quarter amounts to 60.26M USD, increased 34.67
23andMe Holding Co.. EPS for the last quarter amounts to -1.73 USD, decreased -85.03
23andMe Holding Co. (ME) has 769 emplpoyees as of June 19 2026.
Today ME has the market capitalization of 207.53M USD.